Global Information
회사소개 | 문의 | 비교리스트

세계의 코로나바이러스 백신 시장 : 예측과 기회(-2025년)

Global Coronavirus Vaccine Market By Infection Type, By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Forecast & Opportunities, 2025

리서치사 TechSci Research
발행일 2020년 05월 상품 코드 938722
페이지 정보 영문 120 Pages
가격
US $ 4,450 ₩ 5,101,000 Unprintable PDF and Excel (Single User License)
US $ 5,450 ₩ 6,248,000 PDF and Excel (Multi-User License)
US $ 9,450 ₩ 10,834,000 PDF and Excel (Custom Research License)

TechSci Research 보고서는 10% Customization 서비스가 포함되어 있습니다. 보고서에 포함돼 있지 않은 리서치 데이터와 시장 동향을 추가적으로 요청할 수 있습니다. 자세한 사항은 문의하여 주시기 바랍니다.



세계의 코로나바이러스 백신 시장 : 예측과 기회(-2025년) Global Coronavirus Vaccine Market By Infection Type, By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Forecast & Opportunities, 2025
발행일 : 2020년 05월 페이지 정보 : 영문 120 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 코로나바이러스 백신 시장은 예측기간 동안 상당히 빠른 속도로 성장할 것으로 예상됩니다. 세계 코로나바이러스 백신 시장은 전세계 여러 지역에서의 유병률 증가에 힘입어 성장하고 있습니다. 이로 인해 바이러스 예방 필요성이 높아지면서 시장 성장에 긍정적인 영향을 미치고 있으며, 또한 잠재적인 백신 개발을 위한 다양한 제약 기업과 및 생명공학 기업의 연구개발 활동 증가가 시장 의 성장을 촉진할 것으로 예상됩니다.

세계의 코로나바이러스 백신(Coronavirus Vaccine) 시장을 부문별/지역별로 조사했으며, 시장 규모 및 시장 점유율 예측, 촉진요인과 과제, 시장 동향, 경쟁 상황, 기업 개요 등의 정보를 전해드립니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 코로나19(COVID-19)의 영향

제4장 개요

제5장 고객의 견해

제6장 세계의 코로나바이러스 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 감염 유형별(HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2 등)
    • 백신 유형별(불활화 코로나바이러스 백신, 코로나바이러스 약독 생백신, S단백질 기반 코로나바이러스 백신)
    • 제품 유형별(1가 백신, 다가 백신)
    • 투여 경로별(경구, 근육내, 피하)
    • 환자 유형별(소아, 성인)
    • 최종사용자별(병원, 진료소, 연구기관, 기타)
    • 기업별
    • 지역별
  • 제품 시장 맵

제7장 아시아태평양의 코로나바이러스 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 감염 유형별
    • 백신 유형별
    • 제품 유형별
    • 투여 경로별
    • 환자 유형별
    • 최종사용자별
    • 국가별
  • 아시아태평양 : 국가 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국
    • 홍콩
    • 태국
    • 싱가포르

제8장 유럽의 코로나바이러스 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 감염 유형별
    • 백신 유형별
    • 제품 유형별
    • 투여 경로별
    • 환자 유형별
    • 최종사용자별
    • 국가별
  • 유럽 : 국가 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제9장 북미의 코로나바이러스 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 감염 유형별
    • 백신 유형별
    • 제품 유형별
    • 투여 경로별
    • 환자 유형별
    • 최종사용자별
    • 국가별
  • 북미 : 국가 분석
    • 미국
    • 멕시코
    • 캐나다

제10장 남미의 코로나바이러스 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 감염 유형별
    • 백신 유형별
    • 제품 유형별
    • 투여 경로별
    • 환자 유형별
    • 최종사용자별
    • 국가별
  • 남미 : 국가 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제11장 중동 및 아프리카의 코로나바이러스 백신 시장 전망

  • 시장 규모와 예측
  • 시장 점유율과 예측
    • 감염 유형별
    • 백신 유형별
    • 제품 유형별
    • 투여 경로별
    • 환자 유형별
    • 최종사용자별
    • 국가별
  • 중동 및 아프리카 : 국가 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제12장 시장 역학

  • 성장 촉진요인
  • 과제

제13장 시장 동향과 발전

제14장 특허 분석

제15장 경쟁 상황

  • 경쟁 전망
  • 기업 개요
  • 기업 상세
  • 재무
  • 공급/밸류체인 분석
  • 의약품 개발에서 출시까지의 타임라인
    • 백신 승인 현황
  • SWOT 분석
  • 주요 시장의 초점과 지리적 존재
  • 계획된 투자
  • 시장 포지셔닝
  • 주요 기업 개요
    • Inovio Pharmaceuticals, Inc.
    • Moderna, Inc.
    • Novavax, Inc.
    • Johnson & Johnson
    • Pfizer
    • Sanofi
    • Protein Potential, LLC
    • AlphaVax, Inc.
    • Synairgen PLC
    • NanoViricides, Inc.
    • GeneCure, LLC
    • GlaxoSmithKline(GSK)
    • Zydus Cadila
    • Serum Institute
    • Bharat Biotech
    • CanSino Biological Inc
    • FluGen
    • I-Mab Biopharma
    • Medicago
    • Airway Therapeutics

제16장 전략적 권장사항

제17장 면책조항

LSH 20.06.19

Coronaviruses are a group of viruses belonging to the coronaviridae family that can affect both mammals and birds. The common symptoms include mild illness such as common cold, respiratory tract infections, while the lethal symptoms comprise of SARS, MERS, SARS-COV-2, among others.

The ongoing pandemic novel coronavirus disease (COVID-19) is caused due to SARS-COV-2 and generally spreads from animals to humans and then from humans to humans. The disease usually spreads from the saliva droplets of the infected person or the nose discharges of the infected person when they cough or sneeze. The first case of the disease was reported in December 2019 in Wuhan, China and since then, it has spread to various parts of the world infecting millions. As of 13th April 2020, coronavirus has affected around 210 countries & territories with the total number of coronavirus cases reaching 1,854,043 out of which 427,879 have recovered and around 114,291 people have succumbed to the disease.

Global coronavirus vaccine market is expected to grow at a robust rate during the forecast period. The global coronavirus vaccine market is driven by the increasing prevalence of this disease across different parts of the globe. This has increased the need to protect the world from the virus, thereby expected to positively impact the market growth. Furthermore, increasing R&D activities by various pharmaceutical & biotechnology players for the development of potential vaccines is anticipated to foster the market growth. According to WHO, there are 70 coronavirus vaccines under development by different companies and organizations. Out of these, three vaccines are already being tested in human trials. The vaccine developed by the Hong Kong based biopharmaceutical firm CanSino Biologics Inc. and the Beijing Institute of Biotechnology is leading the race and is currently in the second phase of clinical trials. On the other hand, other vaccines developed by the US-based companies Moderna Inc. and Inovio Pharmaceuticals Inc., have also started their human trials.

The global coronavirus vaccine market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end user, company and region. Based on infection type, the market can be categorized into HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2 and others. The SARS-CoV-2 segment is expected to dominate the market since this infection or virus is the cause of the pandemic COVID-19 disease.

Regionally, the global coronavirus vaccine market has been segmented into Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these, Asia-Pacific is expected to witness significant growth during the forecast period in the overall coronavirus vaccine market since China was the epicenter for the novel coronavirus disease and various Chinese companies & research institutes have already started working on various treatment options and vaccines to fight the disease. Additionally, other countries in the region such as India, Singapore, South Korea are also aggressively involved in developing vaccines and other treatments to curb the disease.

Major players operating in the global coronavirus vaccine market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Novavax, Inc., Johnson & Johnson, Pfizer, Sanofi, Protein Potential, LLC, AlphaVax, Inc., Synairgen PLC, NanoViricides, Inc., GeneCure, LLC, GlaxoSmithKline (GSK), Zydus Cadila, Serum Institute, Bharat Biotech, CanSino Biological Inc, FluGen, I-Mab Biopharma, Medicago, Airway Therapeutics and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.

Years considered for this report:

Historical Year: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study:

  • To analyze and estimate the market size of global coronavirus vaccine market from 2015 to 2018.
  • To estimate and forecast the market size of global coronavirus vaccine market from 2019 to 2025 and growth rate until 2025.
  • To classify and forecast global coronavirus vaccine market based on infection type, vaccine type, product type, route of administration, patient type, end user, company and regional distribution.
  • To identify dominant region or segment in the global coronavirus vaccine market.
  • To identify drivers and challenges for global coronavirus vaccine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global coronavirus vaccine market.
  • To conduct pricing analysis for global coronavirus vaccine market.
  • To identify and analyze the profile of leading players operating in global coronavirus vaccine market.
  • To identify key sustainable strategies adopted by market players in global coronavirus vaccine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global coronavirus vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Coronavirus vaccine manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to coronavirus vaccine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global coronavirus vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Coronavirus Vaccine Market, By Infection Type:

HCoV-229E

HCoV-OC43

SARS-CoV

New Haven CoV

HKU1-CoV

MERS-CoV

SARS-CoV-2

Others

  • Global Coronavirus Vaccine Market, By Vaccine Type:

Inactivated Coronavirus Vaccine

Live Attenuated Coronavirus Vaccine

S-Protein Based Coronavirus Vaccine

  • Global Coronavirus Vaccine Market, By Product Type:

Monovalent Vaccine

Multivariant Vaccine

  • Global Coronavirus Vaccine Market, By Route of Administration:

Oral

Intramuscular

Subcutaneous

  • Global Coronavirus Vaccine Market, By Patient Type:

Pediatric

Adult

  • Global Coronavirus Vaccine Market, By End User:

Hospitals

Clinics

Research Institutes

Others

  • Global Coronavirus Vaccine Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Hong Kong
  • Thailand
  • Singapore

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Iran

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global coronavirus vaccine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Coronavirus Vaccine Market

4. Executive Summary

5. Voice of Customer

6. Global Coronavirus Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, New Haven CoV, HKU1-CoV, MERS-CoV, SARS-CoV-2, Others)
    • 6.2.2. By Vaccine Type (Inactivated Coronavirus Vaccine, Live Attenuated Coronavirus Vaccine, S-Protein Based Coronavirus Vaccine)
    • 6.2.3. By Product Type (Monovalent Vaccine v/s Multivariant Vaccine)
    • 6.2.4. By Route of Administration (Oral, Intramuscular, Subcutaneous)
    • 6.2.5. By Patient Type (Pediatric v/s Adult)
    • 6.2.6. By End User (Hospitals, Clinics, Research Institutes, Others)
    • 6.2.7. By Company (2019)
    • 6.2.8. By Region
  • 6.3. Product Market Map

7. Asia-Pacific Coronavirus Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Infection Type
    • 7.2.2. By Vaccine Type
    • 7.2.3. By Product Type
    • 7.2.4. By Route of Administration
    • 7.2.5. By Patient Type
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Coronavirus Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Infection Type
        • 7.3.1.2.2. By Vaccine Type
        • 7.3.1.2.3. By Product Type
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Patient Type
        • 7.3.1.2.6. By End User
    • 7.3.2. India Coronavirus Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Infection Type
        • 7.3.2.2.2. By Vaccine Type
        • 7.3.2.2.3. By Product Type
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Patient Type
        • 7.3.2.2.6. By End User
    • 7.3.3. Australia Coronavirus Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Infection Type
        • 7.3.3.2.2. By Vaccine Type
        • 7.3.3.2.3. By Product Type
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Patient Type
        • 7.3.3.2.6. By End User
    • 7.3.4. Japan Coronavirus Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Infection Type
        • 7.3.4.2.2. By Vaccine Type
        • 7.3.4.2.3. By Product Type
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Patient Type
        • 7.3.4.2.6. By End User
    • 7.3.5. South Korea Coronavirus Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Infection Type
        • 7.3.5.2.2. By Vaccine Type
        • 7.3.5.2.3. By Product Type
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Patient Type
        • 7.3.5.2.6. By End User
    • 7.3.6. Hong Kong Coronavirus Vaccine Market Outlook
      • 7.3.6.1. Market Size & Forecast
        • 7.3.6.1.1. By Value
      • 7.3.6.2. Market Share & Forecast
        • 7.3.6.2.1. By Infection Type
        • 7.3.6.2.2. By Vaccine Type
        • 7.3.6.2.3. By Product Type
        • 7.3.6.2.4. By Route of Administration
        • 7.3.6.2.5. By Patient Type
        • 7.3.6.2.6. By End User
    • 7.3.7. Thailand Coronavirus Vaccine Market Outlook
      • 7.3.7.1. Market Size & Forecast
        • 7.3.7.1.1. By Value
      • 7.3.7.2. Market Share & Forecast
        • 7.3.7.2.1. By Infection Type
        • 7.3.7.2.2. By Vaccine Type
        • 7.3.7.2.3. By Product Type
        • 7.3.7.2.4. By Route of Administration
        • 7.3.7.2.5. By Patient Type
        • 7.3.7.2.6. By End User
    • 7.3.8. Singapore Coronavirus Vaccine Market Outlook
      • 7.3.8.1. Market Size & Forecast
        • 7.3.8.1.1. By Value
      • 7.3.8.2. Market Share & Forecast
        • 7.3.8.2.1. By Infection Type
        • 7.3.8.2.2. By Vaccine Type
        • 7.3.8.2.3. By Product Type
        • 7.3.8.2.4. By Route of Administration
        • 7.3.8.2.5. By Patient Type
        • 7.3.8.2.6. By End User

8. Europe Coronavirus Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Infection Type
    • 8.2.2. By Vaccine Type
    • 8.2.3. By Product Type
    • 8.2.4. By Route of Administration
    • 8.2.5. By Patient Type
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Coronavirus Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Infection Type
        • 8.3.1.2.2. By Vaccine Type
        • 8.3.1.2.3. By Product Type
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Patient Type
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany Coronavirus Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Infection Type
        • 8.3.2.2.2. By Vaccine Type
        • 8.3.2.2.3. By Product Type
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Patient Type
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom Coronavirus Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Infection Type
        • 8.3.3.2.2. By Vaccine Type
        • 8.3.3.2.3. By Product Type
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Patient Type
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy Coronavirus Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Infection Type
        • 8.3.4.2.2. By Vaccine Type
        • 8.3.4.2.3. By Product Type
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Patient Type
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain Coronavirus Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Infection Type
        • 8.3.5.2.2. By Vaccine Type
        • 8.3.5.2.3. By Product Type
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Patient Type
        • 8.3.5.2.6. By End User

9. North America Coronavirus Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Infection Type
    • 9.2.2. By Vaccine Type
    • 9.2.3. By Product Type
    • 9.2.4. By Route of Administration
    • 9.2.5. By Patient Type
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Coronavirus Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Infection Type
        • 9.3.1.2.2. By Vaccine Type
        • 9.3.1.2.3. By Product Type
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Patient Type
        • 9.3.1.2.6. By End User
    • 9.3.2. Mexico Coronavirus Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Infection Type
        • 9.3.2.2.2. By Vaccine Type
        • 9.3.2.2.3. By Product Type
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Patient Type
        • 9.3.2.2.6. By End User
    • 9.3.3. Canada Coronavirus Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Infection Type
        • 9.3.3.2.2. By Vaccine Type
        • 9.3.3.2.3. By Product Type
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Patient Type
        • 9.3.3.2.6. By End User

10. South America Coronavirus Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Infection Type
    • 10.2.2. By Vaccine Type
    • 10.2.3. By Product Type
    • 10.2.4. By Route of Administration
    • 10.2.5. By Patient Type
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Coronavirus Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Infection Type
        • 10.3.1.2.2. By Vaccine Type
        • 10.3.1.2.3. By Product Type
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Patient Type
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina Coronavirus Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Infection Type
        • 10.3.2.2.2. By Vaccine Type
        • 10.3.2.2.3. By Product Type
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Patient Type
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia Coronavirus Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Infection Type
        • 10.3.3.2.2. By Vaccine Type
        • 10.3.3.2.3. By Product Type
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Patient Type
        • 10.3.3.2.6. By End User

11. Middle East and Africa Coronavirus Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Infection Type
    • 11.2.2. By Vaccine Type
    • 11.2.3. By Product Type
    • 11.2.4. By Route of Administration
    • 11.2.5. By Patient Type
    • 11.2.6. By End User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Coronavirus Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Infection Type
        • 11.3.1.2.2. By Vaccine Type
        • 11.3.1.2.3. By Product Type
        • 11.3.1.2.4. By Route of Administration
        • 11.3.1.2.5. By Patient Type
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia Coronavirus Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Infection Type
        • 11.3.2.2.2. By Vaccine Type
        • 11.3.2.2.3. By Product Type
        • 11.3.2.2.4. By Route of Administration
        • 11.3.2.2.5. By Patient Type
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE Coronavirus Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Infection Type
        • 11.3.3.2.2. By Vaccine Type
        • 11.3.3.2.3. By Product Type
        • 11.3.3.2.4. By Route of Administration
        • 11.3.3.2.5. By Patient Type
        • 11.3.3.2.6. By End User
    • 11.3.4. Kuwait Coronavirus Vaccine Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Infection Type
        • 11.3.4.2.2. By Vaccine Type
        • 11.3.4.2.3. By Product Type
        • 11.3.4.2.4. By Route of Administration
        • 11.3.4.2.5. By Patient Type
        • 11.3.4.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Patent Analysis

15. Competitive Landscape

  • 15.1. Competition Outlook
  • 15.2. Company Profiles
  • 15.3. Company Details
  • 15.4. Financials (As Reported)
  • 15.5. Supply/ Value Chain Analysis
  • 15.6. Timelines For Drug Development To Commercial Launch
    • 15.6.1. Status of Approval of vaccines
  • 15.7. SWOT Analysis
  • 15.8. Key Market Focus and Geographical Presence
  • 15.9. Planned Investments
  • 15.10. Market Positioning
  • 15.11. Leading Players Profiled
    • 15.11.1. Inovio Pharmaceuticals, Inc.
    • 15.11.2. Moderna, Inc.
    • 15.11.3. Novavax, Inc.
    • 15.11.4. Johnson & Johnson
    • 15.11.5. Pfizer
    • 15.11.6. Sanofi
    • 15.11.7. Protein Potential, LLC
    • 15.11.8. AlphaVax, Inc.
    • 15.11.9. Synairgen PLC
    • 15.11.10. NanoViricides, Inc.
    • 15.11.11. GeneCure, LLC
    • 15.11.12. GlaxoSmithKline (GSK)
    • 15.11.13. Zydus Cadila
    • 15.11.14. Serum Institute
    • 15.11.15. Bharat Biotech
    • 15.11.16. CanSino Biological Inc
    • 15.11.17. FluGen
    • 15.11.18. I-Mab Biopharma
    • 15.11.19. Medicago
    • 15.11.20. Airway Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer

Back to Top
전화 문의
F A Q